Changes in cardiac heparan sulfate proteoglycan expression and streptozotocin-induced diastolic dysfunction in rats

Imagem de Miniatura
Arquivos
art_STRUNZ_Changes_in_cardiac_heparan_sulfate_proteoglycan_expression_and_2011.PDF (3.13 MB)
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2011
Editora
BIOMED CENTRAL LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CARDIOVASCULAR DIABETOLOGY, v.10, article ID 35, 10p, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Changes in the proteoglycans glypican and syndecan-4 have been reported in several pathological conditions, but little is known about their expression in the heart during diabetes. The aim of this study was to investigate in vivo heart function changes and alterations in mRNA expression and protein levels of glypican-1 and syndecan-4 in cardiac and skeletal muscles during streptozotocin (STZ)-induced diabetes. Methods: Diabetes was induced in male Wistar rats by STZ administration. The rats were assigned to one of the following groups: control (sham injection), after 24 hours, 10 days, or 30 days of STZ administration. Echocardiography was performed in the control and STZ 10-day groups. Western and Northern blots were used to quantify protein and mRNA levels in all groups. Immunohistochemistry was performed in the control and 30-day groups to correlate the observed mRNA changes to the protein expression. Results: In vivo cardiac functional analysis performed using echocardiography in the 10-day group showed diastolic dysfunction with alterations in the peak velocity of early (E) diastolic filling and isovolumic relaxation time (IVRT) indices. These functional alterations observed in the STZ 10-day group correlated with the concomitant increase in syndecan-4 and glypican-1 protein expression. Cardiac glypican-1 mRNA and skeletal syndecan-4 mRNA and protein levels increased in the STZ 30-day group. On the other hand, the amount of glypican in skeletal muscle was lower than that in the control group. The same results were obtained from immunohistochemistry analysis. Conclusion: Our data suggest that membrane proteoglycans participate in the sequence of events triggered by diabetes and inflicted on cardiac and skeletal muscles.
Palavras-chave
Glypican Syndecan-4, Diabetes, Cardiac Muscle
URI
https://observatorio.fm.usp.br/handle/OPI/22868
Referências
  1. Alvarez K, 2002, J CELL BIOCHEM, V85, P703, DOI 10.1002/jcb.10184
  2. Pellieux C, 2001, J CLIN INVEST, V108, P1843, DOI 10.1172/JCI13627
  3. Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5
  4. Cornelison DDW, 2001, DEV BIOL, V239, P79, DOI 10.1006/dbio.2001.0416
  5. Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729
  6. Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105
  7. Bilate AMB, 2003, MICROBES INFECT, V5, P1116, DOI 10.1016/j.micinf.2003.07.001
  8. Schultz JE, 1999, J CLIN INVEST, V104, P709, DOI 10.1172/JCI7315
  9. Scognamiglio R, 1998, J AM COLL CARDIOL, V31, P404, DOI 10.1016/S0735-1097(97)00516-0
  10. Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914
  11. KOJIMA T, 1992, J BIOL CHEM, V267, P4870
  12. Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005
  13. CLARKE MSF, 1995, CIRC RES, V76, P927
  14. Wold LE, 2004, BIOCHEM BIOPH RES CO, V318, P1066, DOI 10.1016/j.bbrc.2004.04.138
  15. BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415
  16. Veugelers M, 1999, J BIOL CHEM, V274, P26968, DOI 10.1074/jbc.274.38.26968
  17. An D, 2006, AM J PHYSIOL-HEART C, V291, pH1489, DOI 10.1152/ajpheart.00278.2006
  18. Facchiano F, 2002, AM J PATHOL, V161, P531, DOI 10.1016/S0002-9440(10)64209-5
  19. Li JA, 1997, CIRC RES, V81, P785
  20. CLARKE MSF, 1993, J CELL SCI, V106, P121
  21. Jensen T, 1997, DIABETES, V46, pS98
  22. Shriver Z, 2002, TRENDS CARDIOVAS MED, V12, P71, DOI 10.1016/S1050-1738(01)00150-5
  23. Pulinilkunnil T, 2006, CARDIOVASC RES, V69, P329, DOI 10.1016/j.cardiores.2005.09.017
  24. SCHNEDL WJ, 1994, DIABETES, V43, P1326, DOI 10.2337/diabetes.43.11.1326
  25. Diamant M, 2003, J AM COLL CARDIOL, V42, P328, DOI 10.1016/S0735-1097(03)00625-9
  26. Matsuda K, 2001, CANCER RES, V61, P5562
  27. Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825
  28. Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8
  29. BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
  30. Aneja A, 2008, AM J MED, V121, P748, DOI 10.1016/j.amjmed.2008.03.046
  31. Asundi VK, 1997, EXP CELL RES, V230, P145, DOI 10.1006/excr.1996.3400
  32. Bollineni JS, 1997, CURR EYE RES, V16, P127, DOI 10.1076/ceyr.16.2.127.5089
  33. Braga João Carlos Ferreira, 2005, Arq Bras Cardiol, V84, P461, DOI 10.1590/S0066-782X2005000600006
  34. Brandan E, 1996, EUR J CELL BIOL, V71, P170
  35. CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V162, P156
  36. DONNELLY R, 2000, BRIT MED J, V320, P1052
  37. Duraisamy Y., 2001, Angiogenesis, V4, P277, DOI 10.1023/A:1016068917266
  38. ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585
  39. Freire Cláudia Maria V, 2007, Arq Bras Endocrinol Metabol, V51, P168, DOI 10.1590/S0004-27302007000200005
  40. Hamon M, 2004, GLYCOBIOLOGY, V14, P311, DOI 10.1093/glycob/cwh038
  41. HASCALL VC, 1994, METHOD ENZYMOL, V230, P390
  42. JESSUP JA, 2011, MENOPAUSE
  43. KARDAMI E, 1991, ANN NY ACAD SCI, V638, P244, DOI 10.1111/j.1749-6632.1991.tb49035.x
  44. Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
  45. KLUEBER KM, 1994, ANAT REC, V239, P18, DOI 10.1002/ar.1092390104
  46. Litwack ED, 1998, DEV DYNAM, V211, P72, DOI 10.1002/(SICI)1097-0177(199801)211:1<72::AID-AJA7>3.0.CO;2-4
  47. MEDINASANCHEZ M, 1991, AM J ANAT, V191, P48, DOI 10.1002/aja.1001910105
  48. MORANO S, 1999, BIOCHEM J, V15, P637
  49. Obunike JC, 2000, ARTERIOSCL THROM VAS, V20, P111
  50. Pires MD, 2003, ARTIF ORGANS, V27, P695, DOI 10.1046/j.1525-1594.2003.07276.x
  51. REDDI AS, 1991, GEN PHARMACOL, V22, P323, DOI 10.1016/0306-3623(91)90457-H
  52. Rossen JD, 1996, CORONARY ARTERY DIS, V7, P133, DOI 10.1097/00019501-199602000-00006
  53. Sagerstrom Charles G., 1996, P83
  54. Salemi Vera M C, 2005, Eur J Echocardiogr, V6, P41, DOI 10.1016/j.euje.2004.06.001
  55. TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829
  56. van den Brom CE, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-25
  57. van den Brom CE, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-39
  58. VANDENBORN J, 1995, DIABETOLOGIA, V38, P1169
  59. VanWinkle WB, 2002, ANAT RECORD, V268, P38, DOI 10.1002/ar.10130
  60. Zhong Y, 2001, AM J PHYSIOL-HEART C, V281, pH1137

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor